Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy

Clin Lung Cancer. 2019 May;20(3):e229-e232. doi: 10.1016/j.cllc.2019.02.014. Epub 2019 Feb 27.
No abstract available

Keywords: ALK secondary mutation; EML4-ALK; Longitudinal monitoring; Resistance mutation; Target sequencing.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aminopyridines
  • Anaplastic Lymphoma Kinase / antagonists & inhibitors
  • Anaplastic Lymphoma Kinase / genetics*
  • Antineoplastic Agents / therapeutic use*
  • Carcinogenesis / genetics
  • Carcinoma, Non-Small-Cell Lung / diagnosis*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Circulating Tumor DNA / analysis
  • Crizotinib / therapeutic use
  • Drug Resistance, Neoplasm
  • Humans
  • Lactams
  • Lactams, Macrocyclic / therapeutic use
  • Liquid Biopsy
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / genetics
  • Male
  • Mutation / genetics*
  • Neoplasm Staging
  • Oncogene Proteins, Fusion / genetics*
  • Organophosphorus Compounds / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles
  • Pyrimidines / therapeutic use

Substances

  • Aminopyridines
  • Antineoplastic Agents
  • Circulating Tumor DNA
  • EML4-ALK fusion protein, human
  • Lactams
  • Lactams, Macrocyclic
  • Oncogene Proteins, Fusion
  • Organophosphorus Compounds
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • Crizotinib
  • Anaplastic Lymphoma Kinase
  • brigatinib
  • lorlatinib